A chimeric peptide-modified SIS membrane, a preparation method therefor and an application thereof. The chimeric peptide-modified SIS membrane is used to promote the expression of ITG-3, ITG-1, BMP2, RUNX2, ALP and OPN, and inhibits the growth of Streptococcus gordonii and Streptococcus sanguinis, thereby enabling the SIS membrane to exert antibacterial, osteogenic and healing-promoting biological functions. The SIS membrane (that is, a chimeric peptide-modified GBR film) can be used for clinical treatment of infectious bone defects.

##STR00001##

The invention is to articles of extracellular matrix. The articles comprise one or more sheets of mammalian extracellular matrix laminated together. A single sheet can be folded over and laminated on 3 sides. Two or more sheets can be laminated to each other at their edges. The sheets can further encase a composition comprising a cell or cells, such as for example, a stem cell. A single sheet can be folded over to encase a composition, or rolled to encase a composition with lamination at either end of the roll, for example. The invention also includes methods of using these articles to regenerate tissue at tissue defects, or heal wounds in damaged tissue.

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.

A composition is disclosed herein that includes isolated ECM-derived nanovesicles and a pharmaceutically acceptable carrier. Methods are producing the ECM-derived nanovesicles are also disclosed. These ECM-derived nanovesicles can be included in pharmaceutical compositions, bioscaffolds, and devices. Methods for using these ECM-derived nanovesicles are provided.

Disclosed are a decellularized matrix material, a preparation method therefor and use thereof. The preparation method includes: subjecting small intestinal submucosa to pre-treatment, and subjecting the small intestinal submucosa after the pre-treatment to swelling treatment, freeze-thaw treatment, oxidase immersion treatment, and surfactant treatment in sequence, so as to obtain the decellularized matrix material. In the present application, the combination of physical swelling, physical freezing and thawing, and chemical elution guarantees a high decellularization efficiency; moreover, by adding the oxidase at an appropriate time during the decellularization treatment process, the oxidase thoroughly permeates into the decellularized matrix, and thereby plays a buffering role in the tissue when the surfactant is applied, ensuring the intactness of the collagen structure in the extracellular matrix.

A tissue prosthesis comprising an extracellular matrix (ECM) composition, the ECM composition comprising decellularized ECM derived from mesothelial tissue and an exogenously added basic fibroblast growth factor (bFGF).

Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies.

Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies.

A sheet structure formed from an extracellular matrix (ECM) composition that includes acellular ECM derived from small intestine submucosa (SIS) tissue, gentamicin and vancomycin. The sheet structure is configured to modulate inflammation of damaged biological tissue and induce cell and tissue proliferation, bioremodeling of the damaged biological tissue, and regeneration of new tissue and tissue structures with site-specific structural and functional properties, when the tissue structure is delivered to the damaged biological tissue.

A method is provided for implanting a valve having at least one valve leaflet within the cardiovascular system of a subject. One step of the method includes preparing a substantially dehydrated bioprosthetic valve and then providing an expandable support member having oppositely disposed first and second ends and a main body portion extending between the ends. Next, the substantially dehydrated bioprosthetic valve is attached to the expandable support member so that the substantially dehydrated bioprosthetic valve is operably secured within the main body portion of the expandable support member. The expandable support member is then crimped into a compressed configuration and placed at a desired location within the cardiovascular system of the subject. Either before or after placement at the desired location, fluid or blood re-hydrates the substantially dehydrated bioprosthetic valve.